Month: April 2017
Clinical Study Protocols: How to Write to Solve Problems Now and Avoid Big Ones in the Future
The identification of different responsibilities, under the clear leadership of the medical writer, is necessary to improve the quality of clinical study protocols – to prevent problems and mistakes that can result later, during conduct of the clinical trial, or afterwards, when reporting on trial results.
Modeling & Simulation for Drug Development & Formulation
A look at how to leverage modeling and simulation technology to enhance all phases of the drug development process.
How AI Tech Is Changing Regulatory Writing
Did you know that you’re likely using artificial intelligence (AI) in your everyday life? For example, the digital music service, Spotify, creates “mood-based” playlists that are curated to users’ musical preferences. Spotify generates these customized play lists using a machine learning algorithm that has learned your unique musical preferences based on your previous interactions with … Continued
Certara Introduces Comprehensive Solution to Prepare, Analyze and Submit Pharmacokinetic (PK) Data
PRINCETON, NJ – Apr. 19, 2017 – Certara today announced the launch of a new solution for preparing, analyzing and submitting PK data in Clinical Data Exchange Standards Consortium (CDISC) format. CDISC supports the acquisition, exchange, submission and archiving of non-clinical and clinical data.
Speaking into the Ether: Challenges of the Virtual Pharma Workplace
In this webinar, Drs. Peter Bonate and Stacey Tannenbaum discussed what kind of technology tools can facilitate a connection with your audience and address the difficulties of speaking into the ether. They offered practical solutions that you can use to strengthen your collaboration in the virtual workplace.
Certara’s d3 Medicine Partners with the Australian Department of Defence
PRINCETON, NJ – Apr. 5. 2017 – Certara today announced that its d3 Medicine company has been selected to conduct a national audit of Australia’s medical countermeasures (MCM) product research and development (R&D) capabilities and capacity.
Isoniazid Clearance is Impaired Among Human Immunodeficiency Virus/Tuberculosis Patients with High Levels of Immune Activation
Optimization of Intestinal Microsomal Preparation in the Rat: A Systematic Approach to Assess the Influence of Various Methodologies on Metabolic Activity and Scaling Factors
1 of 1
